Pregled bibliografske jedinice broj: 1260881
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score // Prostate cancer and prostatic diseases, 25 (2022), 4; 755-761 doi:10.1038/s41391-022-00497-7 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1260881 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
Autori
Huynh-Le, Minh-Phuong ; Karunamuni, Roshan ; Fan, Chun Chieh ; Asona, Lui ; Thompson, Wesley K. ; Martinez, Maria Elena ; Eeles, Rosalind A. ; Kote-Jarai, Zsofia ; Muir, Kenneth R. ; Lophatananon, Artitaya ; Schleutker, Johanna ; Pashayan, Nora ; Batra, Jyotsna ; Grönberg, Henrik ; Neal, David E. ; Nordestgaard, Børge G. ; Tangen, Catherine M. ; MacInnis, Robert J. ; Wolk, Alicja ; Albanes, Demetrius ; Haiman, Christopher A. ; Travis, Ruth C. ; Blot, William J. ; Stanford, Janet L. ; Mucci, Lorelei A. ; West, Catharine M. L. ; Nielsen, Sune F. ; Kibel, Adam S. ; Cussenot, Olivier ; Berndt, Sonja I. ; Koutros, Stella ; Sørensen, Karina Dalsgaard ; Cybulski, Cezary ; Grindedal, Eli Marie ; Menegaux, Florence ; Park, Jong Y. ; Ingles, Sue A. ; Maier, Christiane ; Hamilton, Robert J. ; Rosenstein, Barry S. ; Lu, Yong-Jie ; Watya, Stephen ; Vega, Ana ; Kogevinas, Manolis ; Wiklund, Fredrik ; Penney, Kathryn L. ; Huff, Chad D. ; Teixeira, Manuel R. ; Multigner, Luc ; Leach, Robin J. ; Brenner, Hermann ; John, Esther M. ; Kaneva, Radka ; Logothetis, Christopher J. ; Neuhausen, Susan L. ; De Ruyck, Kim ; Ost, Piet ; Razack, Azad ; Newcomb, Lisa F. ; Fowke, Jay H. ; Gamulin, Marija ; Abraham, Aswin ; Claessens, Frank ; Castelao, Jose Esteban ; Townsend, Paul A. ; Crawford, Dana C. ; Petrovics, Gyorgy ; van Schaik, Ron H. N. ; Parent, Marie-Élise ; Hu, Jennifer J. ; Zheng, Wei ; Mills, Ian G. ; Andreassen, Ole A. ; Dale, Anders M. ; Seibert, Tyler M.
Kolaboracija
UKGPCS collaborators ; APCB (Australian Prostate Cancer BioResource) ; NC-LA PCaP Investigators ; The IMPACT Study Steering Committee and Collaborators ; Canary PASS Investigators ; The Profile Study Steering Committee ; The PRACTICAL Consortium
Izvornik
Prostate cancer and prostatic diseases (1365-7852) 25
(2022), 4;
755-761
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
prostate cancer ; multi-ancestry datasets
Sažetak
Background: Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets. Methods: In total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72, 181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry-the Cohort of Swedish Men (COSM) and the ProtecT study. Hazard ratios (HRs) were estimated to compare men with high versus low PHS for association with clinically significant, with any, and with fatal prostate cancer. The impact of genetic risk stratification on the positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was also measured. Results: The final model (PHS290) had 290 SNPs with non-zero coefficients. Comparing, for example, the highest and lowest quintiles of PHS290, the hazard ratios (HRs) for clinically significant prostate cancer were 13.73 [95% CI: 12.43-15.16] in ProtecT, 7.07 [6.58-7.60] in African ancestry, 10.31 [9.58-11.11] in Asian ancestry, and 11.18 [10.34-12.09] in COSM. Similar results were seen for association with any and fatal prostate cancer. Without PHS stratification, the PPV of PSA testing for clinically significant prostate cancer in ProtecT was 0.12 (0.11-0.14). For the top 20% and top 5% of PHS290, the PPV of PSA testing was 0.19 (0.15-0.22) and 0.26 (0.19-0.33), respectively. Conclusions: We demonstrate better genetic risk stratification for clinically significant prostate cancer than prior versions of PHS in multi-ancestry datasets. This is promising for implementing precision-medicine approaches to prostate cancer screening decisions in diverse populations.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Marija Gamulin
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE